According to the latest filings disclosed by the US Securities and Exchange Commission, Johnson & Johnson and its subsidiary JJDc have reached a significant agreement with gene therapy company MeiraGTx Holdings Plc.

Both parties have agreed to impose a 12-month lock-up period on MeiraGTx shares held after the completion of the transaction. This lock-up arrangement means that relevant parties are not allowed to sell or transfer their MeiraGTx shares during this period. Such a measure is usually seen as a demonstration of confidence in the company’s long-term development prospects and helps to maintain share price stability and market confidence. As a well-known enterprise in the field of gene therapy, MeiraGTx focuses on developing novel treatments for serious diseases. The conclusion of this lock-up agreement marks a further deepening of the strategic partnership between the two parties.